Dosing Guidlines for Adults
Drug Detail for Adult Drugs
Cisplatin
Miscellaneous Agents
Antineoplastic Agents
- General Toxicity Notes
- Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
- Excreted Unchanged %
- 27-45
- Half-Life (NormalESRD) hours
- 0.3-0.5/No data
- Plasma Protein Binding %
- 90
- Volume of Distribution L/kg
- 0.5
- Dose for Normal Renal Function
- 20-50 mg/m2 q24h
- Second Dose
-
- Adjustment for Renal Failure Method
- D
- Adjustment for Renal Failure GFR, mL/min >50 [Recommended Level]
- 100% [A]
- Adjustment for Renal Failure GFR, mL/min 10-50 [Recommended Level]
- 75% [A]
- Adjustment for Renal Failure GFR, mL/min <10 [Recommended Level]
- 50% [A]
- Supplement for Dialysis [Recommendation Level]: IHD
- IHD: Yes, [B]
- Supplement for Dialysis [Recommendation Level]: PD
- PD: Dose for GFR <10, [D]
- Supplement for Dialysis [Recommendation Level]: CRRT
- CRRT: Dose for GFR 10-50, [B]
- References
- Benisovich VI, Silverman L, Slifkin R, Stone N, Cohen E. Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. Cancer. 1996; 77: 160-3. [PMID: 8630924] / Blachley JD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med. 1981; 95: 628-32. [PMID: 7027859] / Gormley PE, Bull JM, LeRoy AF, Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther. 1979; 25: 351-7. [PMID: 761445] / Hirai K, Ishiko O, Sumi T, Kanaoka Y, Ogita S. Kinetics of plasma platinum in a hemodialysis patient receiving repeated doses of cisplatin. Oncol Rep. 2000; 7: 1243-5.[PMID: 11032923]
- Toxicity Notes
- Nephrotoxic. Toxicity reduced by pretreatment hydration and Cl diuresis. Renal Mg++ wasting.